<?xml version="1.0"?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
    article-type="research-article">
    <?properties open_access?>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id>
        <journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id>
        <journal-title-group>
          <journal-title>BMC Cancer</journal-title>
        </journal-title-group>
        <issn pub-type="epub">1471-2407</issn>
        <publisher>
          <publisher-name>BioMed Central</publisher-name>
          <publisher-loc>London</publisher-loc>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmid">31208370</article-id>
        <article-id pub-id-type="pmc">6580637</article-id>
        <article-id pub-id-type="publisher-id">5820</article-id>
        <article-id pub-id-type="doi">10.1186/s12885-019-5820-0</article-id>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Research Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>EGFR exon 20 insertion mutations and response to osimertinib in
            non-small-cell lung cancer</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
            <name>
              <surname>Fang</surname>
              <given-names>Wenfeng</given-names>
            </name>
            <address>
              <email>fangwf@sysucc.org.cn</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <name>
              <surname>Huang</surname>
              <given-names>Yihua</given-names>
            </name>
            <address>
              <email>huangyh2@sysucc.org.cn</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <name>
              <surname>Hong</surname>
              <given-names>Shaodong</given-names>
            </name>
            <address>
              <email>hongshd@sysucc.org.cn</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <name>
              <surname>Zhang</surname>
              <given-names>Zhonghan</given-names>
            </name>
            <address>
              <email>zhangzhongh@sysucc.org.cn</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <name>
              <surname>Wang</surname>
              <given-names>Minghui</given-names>
            </name>
            <address>
              <email>wangminghui01@aliyun.com</email>
            </address>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name>
              <surname>Gan</surname>
              <given-names>Jiadi</given-names>
            </name>
            <address>
              <email>gjdaaa@outlook.com</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Wenjing</given-names>
            </name>
            <address>
              <email>wangwj@origimed.com</email>
            </address>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name>
              <surname>Guo</surname>
              <given-names>Honglin</given-names>
            </name>
            <address>
              <email>guohl@origimed.com</email>
            </address>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Kai</given-names>
            </name>
            <address>
              <email>wangk@origimed.com</email>
            </address>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <name>
              <surname>Zhang</surname>
              <given-names>Li</given-names>
            </name>
            <address>
              <email>zhangli@sysucc.org.cn</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <aff id="Aff1"><label>1</label><institution-wrap>
              <institution-id institution-id-type="ISNI">0000 0004 1803 6191</institution-id>
              <institution-id institution-id-type="GRID">grid.488530.2</institution-id>
              <institution>Department of Medical Oncology, State Key Laboratory of Oncology in South
            China, Collaborative Innovation Center for Cancer Medicine, </institution>
              <institution>Sun Yat-Sen University Cancer Center, </institution>
            </institution-wrap>Guangzhou,
            510060 People&#x2019;s Republic of China </aff>
          <aff id="Aff2"><label>2</label><institution-wrap>
              <institution-id institution-id-type="ISNI">0000 0001 2360 039X</institution-id>
              <institution-id institution-id-type="GRID">grid.12981.33</institution-id>
              <institution>Sun Yat-Sen Memorial Hospital, </institution>
              <institution>Sun Yat-Sen University, </institution>
            </institution-wrap>Guangzhou,
            510220 People&#x2019;s Republic of China </aff>
          <aff id="Aff3"><label>3</label>OrigiMed, Inc, NO.115 XinJunhuan Road, Shanghai, 201114
            People&#x2019;s Republic of China </aff>
        </contrib-group>
        <pub-date pub-type="epub">
          <day>17</day>
          <month>6</month>
          <year>2019</year>
        </pub-date>
        <pub-date pub-type="pmc-release">
          <day>17</day>
          <month>6</month>
          <year>2019</year>
        </pub-date>
        <pub-date pub-type="collection">
          <year>2019</year>
        </pub-date>
        <volume>19</volume>
        <elocation-id>595</elocation-id>
        <history>
          <date date-type="received">
            <day>24</day>
            <month>1</month>
            <year>2019</year>
          </date>
          <date date-type="accepted">
            <day>11</day>
            <month>6</month>
            <year>2019</year>
          </date>
        </history>
        <permissions>
          <copyright-statement>&#xA9; The Author(s). 2019</copyright-statement>
          <license license-type="OpenAccess">
            <license-p><bold>Open Access</bold>This article is distributed under the terms of the
              Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri"
                xlink:href="http://creativecommons.org/licenses/by/4.0/">
              http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted
              use, distribution, and reproduction in any medium, provided you give appropriate
              credit to the original author(s) and the source, provide a link to the Creative
              Commons license, and indicate if changes were made. The Creative Commons Public Domain
              Dedication waiver (<ext-link ext-link-type="uri"
                xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">
              http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made
              available in this article, unless otherwise stated.</license-p>
          </license>
        </permissions>
        <abstract id="Abs1">
          <sec>
            <title>Background</title>
            <p id="Par1">Epidermal growth factor receptor exon 20 insertion (EGFRex20ins) mutations
              represent approximately 4&#x2013;12% of EGFR mutations and are generally refractory to
              the 1st and 2nd generation EGFR tyrosine kinase inhibitors (TKIs). Development of
              effective therapies for patients with EGFRex20ins mutant non-small-cell lung carcinoma
              (NSCLC) represents a great unmet need. Preclinical models have shown that osimertinib
              is active in NSCLC harboring EGFRex20ins, while the antitumor activity of osimertinib
              remains to be evaluated in patients with EGFRex20ins mutations.</p>
          </sec>
          <sec>
            <title>Methods</title>
            <p id="Par2">Tumor genotyping was performed in 2316 Chinese NSCLC cases with targeted
              next generation sequencing (NGS) covering the whole exons of EGFR gene. The frequency
              and genetic characteristics of EGFRexon20ins mutations were analyzed. Furthermore, six
              patients with specific EGFRexon20ins mutations and receiving osimertinib 80&#x2009;mg
              once daily were retrospectively included to assess the antitumor activity and safety
              of monotherapy osimertinib.</p>
          </sec>
          <sec>
            <title>Results</title>
            <p id="Par3">EGFRex20ins mutations were identified in 4.8% (53/1095) of EGFR mutant
              NSCLC and 2.3% (53/2316) of all NSCLC cases. The most frequently identified
              EGFRexon20ins is A767_V769dup (17/53,32.1%). We found that the genetic characteristics
              of EGFRex20ins mutations in Chinese patients with NSCLC were comparable to those
              reported in Caucasian patients. Four patients with osimertinib therapy achieved
              partial response and the rest stable disease. Median progression free survival (PFS)
              was 6.2&#x2009;months (95% confidence interval 5.0&#x2013;12.9&#x2009;months; range
              4.9&#x2013;14.6&#x2009;months). The most common adverse events (AEs) were diarrhea
              (2/6), pruritis (2/6), stomatitis (1/6) and nausea (1/6). No grade 3 or more AEs were
              documented.</p>
          </sec>
          <sec>
            <title>Conclusions</title>
            <p id="Par4">This study revealed that the genetic characteristics of EGFRex20ins
              mutations in Chinese patients with NSCLC were comparable to those reported in
              Caucasian patients. Furthermore, our study firstly demonstrated promising antitumor
              activity of osimertinib in certain EGFRex20ins mutant advanced NSCLC patients,
              indicating that osimertinib treatment for EGFRex20ins positive patients deserves
              further study.</p>
          </sec>
          <sec>
            <title>Electronic supplementary material</title>
            <p>The online version of this article (10.1186/s12885-019-5820-0) contains supplementary
              material, which is available to authorized users.</p>
          </sec>
        </abstract>
        <kwd-group xml:lang="en">
          <title>Keywords</title>
          <kwd>NSCLC</kwd>
          <kwd>EGFRex20ins</kwd>
          <kwd>NGS</kwd>
          <kwd>Osimertinib</kwd>
        </kwd-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>National Key R&amp;D Program of China</institution>
            </funding-source>
            <award-id>2016YFC0905500</award-id>
            <award-id>2016YFC0905503</award-id>
            <principal-award-recipient>
              <name>
                <surname>Zhang</surname>
                <given-names>Li</given-names>
              </name>
            </principal-award-recipient>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">
                  http://dx.doi.org/10.13039/501100001809</institution-id>
                <institution>National Natural Science Foundation of China</institution>
              </institution-wrap>
            </funding-source>
            <award-id>81772476</award-id>
            <award-id>81872499</award-id>
            <award-id>81702283</award-id>
            <award-id>81602005</award-id>
            <principal-award-recipient>
              <name>
                <surname>Fang</surname>
                <given-names>Wenfeng</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>Shaodong</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Li</given-names>
              </name>
            </principal-award-recipient>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>Science and Technology Program of Guangdong</institution>
            </funding-source>
            <award-id>2017B020227001</award-id>
            <principal-award-recipient>
              <name>
                <surname>Zhang</surname>
                <given-names>Li</given-names>
              </name>
            </principal-award-recipient>
          </award-group>
        </funding-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>issue-copyright-statement</meta-name>
            <meta-value>&#xA9; The Author(s) 2019</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec id="Sec1">
        <title>Background</title>
        <p id="Par19">During the past decades, the identification of specific genomic aberrations
          and their corresponding targeted therapies have significantly improved the outcome and
          quality of life for patients with non-small-cell lung cancer (NSCLC). Epidermal growth
          factor receptor (EGFR) mutation is the first identified targetable driver mutation that
          was reported in about 17 and 50% of lung adenocarcinoma in Caucasians and Asians,
          respectively [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr"
            rid="CR3">3</xref>]. The most common cluster of mutations in EGFR gene include inframe
          deletions around the LeuArgGluAla motif (residues 746&#x2013;750) of exon 19, and the
          Leu858Arg (L858R) point mutation in exon 21, each accounting for about 45% of all EGFR
          mutations. These mutations are termed classic EGFR mutations and are more common in tumors
          in women, Asians, never smokers, and those with adenocarcinoma [<xref ref-type="bibr"
            rid="CR4">4</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>]. The frequency and
          distribution of EGFR mutations in patients with different ethnic backgrounds also differ [<xref
            ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
        <p id="Par20">Patients with classic EGFR mutations generally have profound radiographic and
          clinical response to monotherapy EGFR tyrosine kinase inhibitors (TKIs) [<xref
            ref-type="bibr" rid="CR9">9</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>].
          However, some unclassical EGFR mutations are associated with poor responses with
          reversible EGFR TKIs [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr"
            rid="CR14">14</xref>]. Among these are most EGFR exon 20 insertion (EGFRex20ins)
          mutations reported as far. Exon 20 of EGFR encompasses nucleotides that translate into
          amino acid at position 762 to 823. It contains a C-helix (residues 762&#x2013;766) and the
          loop following C-helix (residues 767&#x2013;774), where the insertions could induce
          ligand-independent EGFR pathway activation and give rise to tumorigenesis [<xref
            ref-type="bibr" rid="CR15">15</xref>]. The true frequency of EGFRex20ins mutations
          within the EGFR mutant lung cancer is inconsistent, contributing to roughly 4&#x2013;12%
          of all EGFR mutations identified [<xref ref-type="bibr" rid="CR16">16</xref>&#x2013;<xref
            ref-type="bibr" rid="CR18">18</xref>]. In most reports, EGFRex20ins mutations are more
          common in tumors among never-smokers [<xref ref-type="bibr" rid="CR16">16</xref>, <xref
            ref-type="bibr" rid="CR18">18</xref>]. However, the genetic and clinical characteristics
          of NSCLCs harboring EGFRex20ins mutations in Asian populations remain unknown due to the
          lack of large comprehensive genomic studies.</p>
        <p id="Par21">Preclinical and clinical studies have shown that most EGFRex20ins (except for
          few subtypes such as EGFR A763_Y764insFQEA) mutant tumors confer resistance to the 1st and
          2nd generation EGFR TKIs because the insertions produce steric hindrance and activate EGFR
          without saliently decreasing affinity for ATP or enhancing affinity for EGFR TKIs [<xref
            ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x2013;<xref
            ref-type="bibr" rid="CR23">23</xref>]. Several clinical studies specifically involving
          tumors with EGFRex20ins mutations are ongoing, with some of them showing preliminary
          promising activity [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr"
            rid="CR25">25</xref>]. However, there are still no established molecular targeted drugs
          for NSCLC patients with EGFRx20ins mutations. Development of more effective therapeutics
          for these specific patients represents a great unmet need.</p>
        <p id="Par22">Osimertinib is an oral, potent, irreversible EGFR TKI selective for
          sensitizing EGFR and EGFR T790&#x2009;M resistance mutations. Preclinical studies have
          reported that osimertinib was active in EGFRex20ins mutant cell lines and tumor xenografts
          with a wide therapeutic window [<xref ref-type="bibr" rid="CR26">26</xref>&#x2013;<xref
            ref-type="bibr" rid="CR29">29</xref>]. However, whether the preclinical activity of
          osimertinib could translate into clinical effect remains unclear.</p>
        <p id="Par23">Herein, we explored the characteristics of EGFRex20ins, as well as the
          patterns of co-mutations (mutually exclusive or inclusive) in Chinese NSCLC patients. In
          addition, we assessed the safety and antitumor activity of osimertinib in six advanced
          NSCLC patients with various EGFRex20ins mutations.</p>
      </sec>
      <sec id="Sec2">
        <title>Methods</title>
        <sec id="Sec3">
          <title>Patients</title>
          <p id="Par24">The study included a cohort of patients who were referred to OrigiMed
            (Shanghai, China) for targeted next generation sequencing (NGS) test in China between
            August 2016 and July 2018. Patient samples and clinical information including gender,
            age and histologic subtypes were retrieved at the time of referral. Six patients with
            EGFRex20ins mutant stage IV NSCLC who were treated with osimertinib 80&#x2009;mg once
            daily were included to evaluate the antitumor activity of osimertinib. Data were
            retrospectively collected from digital medical records. The study was approved by the
            Institutional Review Board of SYSUCC and written informed consent was obtained for each
            patient prior to sample collection. Written consents were obtained from parents if
            patients were under 16&#x2009;years old.</p>
        </sec>
        <sec id="Sec4">
          <title>EGFR ex20ins and co-mutations analysis</title>
          <p id="Par25">DNA from Formalin-fixed, paraffin-embedded tumor tissue and matched blood
            samples was extracted. Comprehensive genomic profiling was performed by NGS with a 37 or
            450 cancer related gene panel covering the whole exons of EGFR gene at a mean coverage
            depth of &gt;800X (1547 cases with 37 panel, and 769 cases with 450 panel). The genomic
            alterations including single base substitution, insertions/deletions, copy number
            variations, as well as gene rearrangement and fusions were assessed. As for six patients
            treated with osimertinib, genetic status was also determined through NGS prior to
            osimertinib.</p>
        </sec>
        <sec id="Sec5">
          <title>Response evaluation</title>
          <p id="Par26">All six patients received oral osimertinib 80&#x2009;mg once daily.
            Radiological follow-up was performed at the first months then once every 2 months with
            computed tomography (CT) of the thorax and upper abdomen. Regular cerebral magnetic
            resonance imaging (MRI) with CT was carried out once any patient was confirmed brain
            metastasis. Response was assessed according to Response Criteria in Solid Tumors
            (RECIST) 1.1 [<xref ref-type="bibr" rid="CR30">30</xref>]. Progression-free survival
            (PFS) was defined as the interval from the date of initiation of osimertinib therapy to
            the date of disease progression or death from any cause, whichever occurred first.</p>
        </sec>
        <sec id="Sec6">
          <title>Statistical analyses</title>
          <p id="Par27">The statistical analyses were performed using the SPSS 20.0 (Chicago, IL,
            USA). The difference in the frequency of each group was analyzed by the Chi-square test
            or Fisher&#x2019;s exact test. The median age between groups was compared using
            nonparametric test. A two-sided <italic>p</italic> value &lt;&#x2009;0.05 was considered
            statistically significant.</p>
        </sec>
      </sec>
      <sec id="Sec7">
        <title>Results</title>
        <sec id="Sec8">
          <title>Frequency and genetic characteristics of EGFRex20ins mutations</title>
          <p id="Par28">Among the 2316 unselective NSCLC tumors, EGFR mutations were identified in
            1095 cases (47.3%). EGFRex20ins mutations were detected in 53 cases, contributing 2.3%
            of all NSCLC cases and 4.8% of EGFR-mutant tumors. Compared with Foundation Medicine
            (FM) data representing the largest EGFRex20ins cohort, we found that although EGFR
            mutations were much more common in our Chinese NSCLC patients than that of Western
            population (47.3% vs 15.5% in FM), EGFRex20ins mutation represented a much smaller group
            in EGFR mutant NSCLC (4.8% vs 11.7% in FM, <italic>p</italic>&#x2009;&lt;&#x2009;0.001)
            [<xref ref-type="bibr" rid="CR17">17</xref>]. Of note, our result was comparable with FM
            cohort in frequency of EGFRex20ins in total NSCLC (2.3% vs. 1.8% in FM, <italic>p</italic>&#x2009;=&#x2009;0.12,
            Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The smaller proportion of
            EGFRex20ins in Chinese populations is due to the larger scale of EGFR mutations than
            western groups.<fig id="Fig1">
              <label>Fig. 1</label>
              <caption>
                <p>Frequency of EGFRex20ins mutations. <bold>a</bold>. Comparison of EGFRex20ins
            frequency in total NSCLC patients (OrigiMed 2.3% vs. FM 1.8%, <italic>p</italic>&#x2009;=&#x2009;0.12)
            and adenocarcinoma patients (OrigiMed 2.7% vs. FM 2.3%, <italic>p</italic>
            &#x2009;=&#x2009;0.32). <bold>b</bold>. Comparison of EGFRex20ins frequency in
            EGFR-mutant NSCLC patients (OrigiMed 4.8% vs. FM 11.7%, <italic>p</italic>&#x2009;&lt;&#x2009;0.001)
            and EGFR-mutant adenocarcinoma patients (OrigiMed 4.8% vs. FM 13.9%, <italic>p</italic>&#x2009;&lt;&#x2009;0.001).
            EGFRex20ins, epidermal growth factor receptor exon 20 insertions; NSCLC, non-small cell
            lung cancer; FM: Foundation Medicine. * <italic>p</italic>&#x2009;&lt;&#x2009;0.001</p>
              </caption>
              <graphic xlink:href="12885_2019_5820_Fig1_HTML" id="MO1" />
            </fig></p>
          <p id="Par29">The demographic and clinical characteristics of these patients are
            summarized in Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2"
              ref-type="table">2</xref>. Of the patients with EGFR mutations, EGFRex20ins ranked the
            fourth most common type, following EGFR exon 19 deletions (436/1095, 39.8%), L858R
            (410/1095, 37.4%) and T790&#x2009;M mutations (58/1095, 5.3%) (Fig.&#xA0;<xref
              rid="Fig2" ref-type="fig">2</xref>a). The majority of EGFRex20ins mutations were
            identified in lung adenocarcinoma (92.5%, 49/53). EGFRex20ins were also detected in two
            adenosquamous cases and two NSCLC not otherwise specified (NOS). Median age of patients
            with exon 20 insertion is 57 (31&#x2013;85) years.<table-wrap id="Tab1">
              <label>Table 1</label>
              <caption>
                <p>Histologic and clinical characteristics of non-small cell lung cancer patients
            tested in this study</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th />
                    <th>Adenocarcinoma</th>
                    <th>Squamous</th>
                    <th>Others <sup>a</sup></th>
                    <th>Total</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>Total cases</td>
                    <td>1820</td>
                    <td>290</td>
                    <td>206</td>
                    <td>2316</td>
                  </tr>
                  <tr>
                    <td>&#x2003;Median age</td>
                    <td>60(26&#x2013;92)</td>
                    <td>62(30&#x2013;88)</td>
                    <td>60(12&#x2013;83)</td>
                    <td>61(12&#x2013;92)</td>
                  </tr>
                  <tr>
                    <td>&#x2003;Sex, M/F</td>
                    <td>917/903</td>
                    <td>247/43</td>
                    <td>144/62</td>
                    <td>1308/1008</td>
                  </tr>
                  <tr>
                    <td>EGFR mutant cases</td>
                    <td>1021</td>
                    <td>11</td>
                    <td>63</td>
                    <td>1095</td>
                  </tr>
                  <tr>
                    <td>&#x2003;Frequency in total</td>
                    <td>56.1%</td>
                    <td>3.8%</td>
                    <td>30.6%</td>
                    <td>47.3%</td>
                  </tr>
                  <tr>
                    <td>&#x2003;Median age</td>
                    <td>60(26&#x2013;86)</td>
                    <td>64(38&#x2013;89)</td>
                    <td>57(27&#x2013;74)</td>
                    <td>60(26&#x2013;89)</td>
                  </tr>
                  <tr>
                    <td>&#x2003;Sex, M/F</td>
                    <td>397/624</td>
                    <td>5/6</td>
                    <td>28/35</td>
                    <td>430/665</td>
                  </tr>
                  <tr>
                    <td>EGFRex20ins cases</td>
                    <td>49</td>
                    <td>0</td>
                    <td>4</td>
                    <td>53</td>
                  </tr>
                  <tr>
                    <td>&#x2003;Frequency in EGFR mutant</td>
                    <td>4.8%</td>
                    <td>0</td>
                    <td>6.3%</td>
                    <td>4.8%</td>
                  </tr>
                  <tr>
                    <td>&#x2003;Frequency in total</td>
                    <td>2.7%</td>
                    <td>0</td>
                    <td>1.9%</td>
                    <td>2.3%</td>
                  </tr>
                  <tr>
                    <td>&#x2003;Median age</td>
                    <td>57(31&#x2013;85)</td>
                    <td>&#x2013;</td>
                    <td>56.5(49&#x2013;70)</td>
                    <td>57(31&#x2013;85)</td>
                  </tr>
                  <tr>
                    <td>&#x2003;Sex, M/F</td>
                    <td>26/23</td>
                    <td>&#x2013;</td>
                    <td>2/2</td>
                    <td>28/25</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <p><sup>a</sup> Other pathological type in NSCLC, including adenosquamous lung
            cancer, NSCLC not otherwise specified, large cell lung cancer, neuroendocrine carcinoma
            and sarcomatoid carcinoma</p>
                <p><italic>M/F</italic> male/female; EGFRex20ins, epidermal growth factor receptor
            exon 20 insertions, <italic>NSCLC</italic> non-small cell lung cancer</p>
              </table-wrap-foot>
            </table-wrap><table-wrap
              id="Tab2">
              <label>Table 2</label>
              <caption>
                <p>Clinical comparison of EGFR ex20ins NSCLC with EGFR</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th />
                    <th>EGFR 20ins</th>
                    <th>EGFR WT</th>
                    <th>EGFR 19del</th>
                    <th>EGFR L858R</th>
                    <th>EGFR T790&#x2009;M</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>Median age</td>
                    <td>57</td>
                    <td>61</td>
                    <td>59.5</td>
                    <td>62</td>
                    <td>59</td>
                  </tr>
                  <tr>
                    <td>&#x2003;<italic>p</italic> value vs. EGFR ex20ins</td>
                    <td />
                    <td>0.399</td>
                    <td>0.897</td>
                    <td>0.206</td>
                    <td>0.792</td>
                  </tr>
                  <tr>
                    <td>Sex, M/F(%M)</td>
                    <td>28/25(53%)</td>
                    <td>878/343(72%)</td>
                    <td>177/259(41%)</td>
                    <td>130/280(32%)</td>
                    <td>21/37(36%)</td>
                  </tr>
                  <tr>
                    <td>&#x2003;<italic>p</italic> value vs. EGFR ex20ins</td>
                    <td />
                    <td>0.003</td>
                    <td>0.088</td>
                    <td>0.002</td>
                    <td>0.078</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <p>WT and EGFR mutant (19del/L858R/ T790&#x2009;M) NSCLC</p>
                <p><italic>WT</italic>wild type</p>
              </table-wrap-foot>
            </table-wrap><fig
              id="Fig2">
              <label>Fig. 2</label>
              <caption>
                <p>Distribution of EGFR mutations and EGFR exon 20 mutation types and EGFRex20ins in
            this study. <bold>a</bold>. Distribution of EGFR mutations. <bold>b</bold>. Distribution
            of EGFR exon 20 mutation types and EGFRex20ins mutations</p>
              </caption>
              <graphic xlink:href="12885_2019_5820_Fig2_HTML" id="MO2" />
            </fig></p>
          <p id="Par30">In total, 20 different variants of exon EGFRex20ins were identified in 53
            NSCLC patients. The most frequent variant is A767_V769dup (32.1%, 17/53), followed by
            P772_H773dup (4/53, 7.5%), S768_D770dup (4/53, 7.5%), N771_H773dup (4/53, 7.5%),
            A763_Y764insFQEA (3/53, 5.7%). Unique EGFRex20ins mutations detected by NGS were
            summarized in Fig. <xref rid="Fig2" ref-type="fig">2</xref>b.</p>
          <p id="Par31">EGFRex20ins tended to be exclusive with NSCLC driver genes such as <italic>
            EGFR</italic> mutation ERBB2, ALK, BRAF and RET mutations. The most common co-mutations
            were TP53 (49.1%). Co-mutation pattern compared with EGFR ex19dels, L858R, T790&#x2009;M
            and other EGFR uncommon mutations were summarized in Additional file <xref rid="MOESM1"
              ref-type="media">1</xref>: Figure S1 and Additional file <xref rid="MOESM2"
              ref-type="media">2</xref>: Figure S2.</p>
        </sec>
        <sec id="Sec9">
          <title>Antitumor activity of monotherapy Osimertinib for patients with EGFRex20ins
            mutations</title>
          <p id="Par32">From August 28th, 2017 to April 30th, 2018, six patients with stage IV lung
            adenocarcinoma bearing EGFRex20ins started osimertinib treatment. Median follow-up time
            was 6.2&#x2009;months. Previous treatment, detailed mutation characteristics and the
            outcome of osimertinib are shown in Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>.
            All the patients had stage IV lung adenocarcinoma and predominantly females (5/6).
            Before osimertinib treatment, four patients were observed metastasis in lungs and
            pleura. Patient 5 was diagnosed with brain metastasis and patient 6 with bone
            metastasis. The median age is 64&#x2009;years old. Two patients received osimertinib as
            first line therapy and two patients had previous treatment with other EGFR TKIs. Per
            RECISIT 1.1, four (67.7%) patients achieved partial response (PR) and the remaining two
            patients (33.3%) obtained stable disease (SD). Median progression-free survival (PFS)
            was 6.2&#x2009;months (95% confidence interval 5.0&#x2013;12.9&#x2009;months; range
            4.9&#x2013;14.6&#x2009;months). Treatment-related adverse events (AEs) included diarrhea
            (2/6), pruritus (2/6), stomatitis (1/6) and nausea (1/6). No grade 3 or more AEs were
            documented. At data cut-off (December 1st, 2018), Two patients had sustaining disease
            control and remained on osimertinib treatment, while the other four patients had
            progressive disease (PD) ultimately.<table-wrap id="Tab3">
              <label>Table 3</label>
              <caption>
                <p>Mutation characteristics and outcome of osimertinib treatment</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th>Patient</th>
                    <th>Age</th>
                    <th>Sex</th>
                    <th>Previous Systematic therapy</th>
                    <th>Previous EGFR TKI Treatment</th>
                    <th>Mutations <sup>a</sup> Before osimertinib (MAF)</th>
                    <th>Best Response</th>
                    <th>PFS</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>1</td>
                    <td>63Y</td>
                    <td>F</td>
                    <td>None</td>
                    <td>None</td>
                    <td>
                      <p>EGFR</p>
                      <p>p. A767_V769dup</p>
                      <p>(3.48%)</p>
                    </td>
                    <td>PR</td>
                    <td>6.0&#x2009;m</td>
                  </tr>
                  <tr>
                    <td>2</td>
                    <td>59Y</td>
                    <td>F</td>
                    <td>Yes</td>
                    <td>None</td>
                    <td>
                      <p>EGFR</p>
                      <p>p. S768_D770dup</p>
                      <p>(1.75%)</p>
                    </td>
                    <td>PR Treatment ongoing</td>
                    <td>14.6&#x2009;m</td>
                  </tr>
                  <tr>
                    <td>3</td>
                    <td>69Y</td>
                    <td>M</td>
                    <td>None</td>
                    <td>None</td>
                    <td>
                      <p>EGFR</p>
                      <p>p. N771_P772insL</p>
                      <p>(47%)</p>
                    </td>
                    <td>SD</td>
                    <td>4.9&#x2009;m</td>
                  </tr>
                  <tr>
                    <td>4</td>
                    <td>70Y</td>
                    <td>F</td>
                    <td>Yes</td>
                    <td>afatinib</td>
                    <td>
                      <p>EGFR</p>
                      <p>p. S768_D770dup</p>
                      <p>(3%)</p>
                    </td>
                    <td>SD Treatment ongoing</td>
                    <td>11.2&#x2009;m</td>
                  </tr>
                  <tr>
                    <td>5</td>
                    <td>63Y</td>
                    <td>F</td>
                    <td>Yes</td>
                    <td>None</td>
                    <td>
                      <p>EGFR</p>
                      <p>p. D770_N771insG</p>
                      <p>(24%)</p>
                    </td>
                    <td>PR</td>
                    <td>6.4&#x2009;m</td>
                  </tr>
                  <tr>
                    <td>6</td>
                    <td>65Y</td>
                    <td>F</td>
                    <td>None</td>
                    <td>gefitinib</td>
                    <td>
                      <p>EGFR</p>
                      <p>p. A763_Y764insFQEA (0.2%)</p>
                      <p>T790&#x2009;M (0.3%)</p>
                    </td>
                    <td>PR</td>
                    <td>5.1&#x2009;m</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <p><sup>a</sup> Mutations predicting EGFR TKI treatment</p>
                <p><italic>TKI</italic> tyrosine kinase inhibitor, <italic>MAF</italic> mutation
            allele fraction, <italic>PFS</italic> progression free survival, <italic>PR</italic>
            partial response, <italic>SD</italic> stable disease</p>
              </table-wrap-foot>
            </table-wrap></p>
          <p id="Par33">Patient 1 had EGFR A767_V769dup mutation and received first-line therapy
            with osimertinib. The patient achieved PR and the PFS was 6.0&#x2009;months. PR was also
            observed in patient 2 (EGFR S768_D770dup), with a PFS of 14.6+ months. The patient was
            still on treatment at data cutoff. Patient 3 was identified with a novel EGFRex20ins
            mutation (EGFR N771_P772insL), which had not been reported before. The patient had SD as
            best response under first line osimertinib treatment and transferred to other treatment
            after 4.9&#x2009;months due to enlarged pleural nodules. Patient 4 harbored the same
            EGFRex20ins mutation as that of patient 2 and attained SD with a PFS of 11.2+ months.
            Both patient 2 and patient 4 remained on osimertinib treatment. Patient 5 was confirmed
            with multiple cerebral metastasis and experienced dizzy and vomiting when diagnosed as
            stage IV adenocarcinoma. The patient was treated with first line chemotherapy with the
            best response of PD. Thereafter, the patient started osimertinib and exhibited salient
            clinical improvement and a reduction of nearly half the tumor burden. The patient had PD
            finally due to new onset bone metastasis, with a PFS of 6.4&#x2009;months. Patient 6 was
            initially diagnosed as lung adenocarcinoma harboring EGFR A763_Y764insFQEA. The patients
            started gefitinib treatment with a best response of PR and PFS of 9.0&#x2009;months. At
            disease progression, the patients had rebiopsy and his tumor was found to had EGFR
            A763_Y764insFQEA and EGFR T790&#x2009;M. Thereafter, the patient was treated with
            osimertinib and attained PR. The patient experienced PD eventually due to brain
            metastasis and achieved a PFS of 5.1&#x2009;months. CT scans performed prior to
            (baseline) and after osimertinib treatment are demonstrated in Fig.&#xA0;<xref
              rid="Fig3" ref-type="fig">3</xref>. Tumor shrinkage for each patient is shown in
            Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>.<fig id="Fig3">
              <label>Fig. 3</label>
              <caption>
                <p>CT scans of the thorax performed before (baseline) and after osimertinib
                  treatment (PR or SD). CT, computed tomography; PR, partial response; SD, stable
            disease</p>
              </caption>
              <graphic xlink:href="12885_2019_5820_Fig3_HTML" id="MO3" />
            </fig><fig
              id="Fig4">
              <label>Fig. 4</label>
              <caption>
                <p>Maximum change in tumor size according to Response Criteria in Solid Tumors
            (RECIST) 1.1. Orange grid indicates partial response and gray grid stable disease</p>
              </caption>
              <graphic xlink:href="12885_2019_5820_Fig4_HTML" id="MO4" />
            </fig></p>
        </sec>
      </sec>
      <sec id="Sec10">
        <title>Discussion</title>
        <p id="Par34">Based on a large-scale study including 2316 NSCLC patient, our study
          demonstrated the EGFRex20ins distribution in EGFR mutant Chinese patients (4.8%), the most
          common EGFRex20ins mutation (A767_V769dup) and co-mutation (TP53), as well as clinical
          characteristics of EGFRex20ins in Chinese NSCLC patients. As for six EGFRex20ins positive
          patients with osimertinib treatment, four (67.7%) patients achieved PR and two SD, with
          disease control rate 100%.</p>
        <p id="Par35">To our knowledge, our study represents the largest NGS based study on Chinese
          EGFRex20ins mutant NSCLC patients. We found that frequency of Chinese EGFRex20ins in total
          NSCLC (2.3%) was comparable with that of western groups in FM cohort [<xref
            ref-type="bibr" rid="CR17">17</xref>]. Although the proportion of EGFR mutant patients
          was much larger in our Chinese cohort (47.3% vs 15.5%), which consists with previous
          studies [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>],
          exon 20 insertions accounted for a smaller proportion compared to FM cohort in EGFR mutant
          NSCLC (4.8% vs. 11.7%, <italic>p</italic>&#x2009;&lt;&#x2009;0.001) [<xref ref-type="bibr"
            rid="CR17">17</xref>]. This might mainly due to different EGFR mutation proportion
          between Asians and Americans, rather than sequencing technology issue as discussed in
          a&#xA0;previous study [<xref ref-type="bibr" rid="CR17">17</xref>]. In the contrast,
          proportion of exon 20 insertion in EGFR- mutant patients in our study is similar to those
          reported in other Asian cohorts, ranging from 3.6&#x2013;4% [<xref ref-type="bibr"
            rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. These results
          revealed a concordance in the prevalence of EGFRex20ins between Chinese and Western
          populations in NSCLC.</p>
        <p id="Par36">The genetic Chinese characteristics of EGFRex20ins is similar to that of
          western populations, including the majority of unique mutations and the most prevalent
          co-mutation [<xref ref-type="bibr" rid="CR17">17</xref>]. EGFRex20ins detected in our
          study also tended to be exclusive with other NSCLC oncogenic drivers including ERBB2,
          BRAF, ALK, KRAS and RET mutations.</p>
        <p id="Par37">Most EGFRex20ins mutations (with the exception of a few subtypes such as
          A763_Y764insFQEA) are associated with poor responses with the 1st and 2nd generation EGFR
          TKIs [<xref ref-type="bibr" rid="CR19">19</xref>&#x2013;<xref ref-type="bibr" rid="CR23">
          23</xref>]. Previous clinical studies including combination therapy of afatinib plus
          cetuximab or monotherapy of Poziotinib have demonstrated good therapeutic efficacy in some
          EGFRex20ins mutations positive NSCLC patients [<xref ref-type="bibr" rid="CR24">24</xref>, <xref
            ref-type="bibr" rid="CR25">25</xref>]. However, the high proportion of severe AEs
          including skin toxicity and diarrhea of these therapies might limit their universal
          clinical applying in future. Several preclinical studies have proved that osimertinib was
          active in specific lung cancer cell lines with EGFRex20ins mutations [<xref
            ref-type="bibr" rid="CR26">26</xref>&#x2013;<xref ref-type="bibr" rid="CR29">29</xref>],
          while the clinical activity of the 3rd generation EGFR TKIs in EGFRex20ins tumors remains
          unknown. Our study showed promising antitumor activity of osimertinib in NSCLC patients
          harboring certain EGFRex20ins mutations, with four patients attaining PR and two patients
          SD. Median PFS with osimertinib was 6.2&#x2009;months, which was numerically higher than
          that with the 1st generation TKIs and afatinib [<xref ref-type="bibr" rid="CR19">19</xref>
          , <xref ref-type="bibr" rid="CR22">22</xref>]. We also for the first time reported a novel
          EGFRex20ins mutation, EGFR N771_P772insL, in lung adenocarcinoma.</p>
        <p id="Par38">Despite the documented activity of osimertinib in our six patients, in vitro
          study still demonstrated limited osimertinib effect in several EGFRex20ins mutant cell
          lines [<xref ref-type="bibr" rid="CR26">26</xref>&#x2013;<xref ref-type="bibr" rid="CR29">
          29</xref>]. Whether other EGFRex20ins mutant tumors could response to osimertinib warrants
          further study. These studies indicate EGFRex20ins is a heterogeneous group of EGFR
          mutation and deserves more researches to fully determine osimertinib sensitivity in
          different EGFRex20ins tumors.</p>
        <p id="Par39">A recent case report has showed that an advanced NSCLC patient with
          EGFRex20ins mutation, S768_D770dup, responded to osimertinib 160&#x2009;mg daily [<xref
            ref-type="bibr" rid="CR33">33</xref>]. The mutation detected was the same as that of
          patient 2 and patient 4, which might suggest favorable lower-dose osimertinib efficacy in
          tumors bearing EGFR S768_D770dup mutation. Another case report also suggested that EGFR
          H773L/V774&#x2009;M, an EGFR exon 20 mutation, could be suppressed by osimertinib [<xref
            ref-type="bibr" rid="CR34">34</xref>], further supporting the osimertinib effect in
          specific EGFR exon 20 mutations.</p>
        <p id="Par40">In addition, considering that EGFR T790&#x2009;M was identified in patient 6
          harboring EGFR A763_Y764insFQEA after acquired resistance to gefitinib, we found that <italic>
          EGFR</italic> T790&#x2009;M served as a potential resistant mechanism in EGFR
          A763_Y764insFQEA positive NSCLC patients and occurrence of both mutations could be
          targeted by osimertinib. This is the first case showing that T790&#x2009;M mediated the
          acquired resistance to gefitinib for patient with EGFR A763_Y764insFQEA and osimertinib
          treatment was effective for patient with both EGFR A763_Y764insFQEA and EGFR
          T790&#x2009;M.</p>
        <p id="Par41">Still, there are several limitations in the study. Firstly, panels of NGS
          performed on patients are not uniform, contributing to relatively incomprehensive genetics
          statistics in patients with small panels. Secondly, although all six patients in our study
          acquired disease control, the sample size is too small to establish the therapeutic
          efficacy of osimertinib in patients with EGFRex20ins.</p>
      </sec>
      <sec id="Sec11">
        <title>Conclusions</title>
        <p id="Par42">In summary, our study revealed no significant difference in the prevalence and
          genetic characteristics of EGFRex20ins between Chinese and Western populations in NSCLC.
          Moreover, promising antitumor activity of osimertinib was observed in specific EGFRex20ins
          positive NSCLC patients, more studies are urgently needed to fully determine osimertinib
          effect in NSCLC patients with different EGFRex20ins mutations.</p>
      </sec>
      <sec sec-type="supplementary-material">
        <title>Additional files</title>
        <sec id="Sec12">
          <p>
            <supplementary-material content-type="local-data" id="MOESM1">
              <media xlink:href="12885_2019_5820_MOESM1_ESM.jpg">
                <label>Additional file 1:</label>
                <caption>
                  <p><bold>Figure S1.</bold> EGFR ex20ins and co-mutation pattern. (JPG 186 kb)</p>
                </caption>
              </media>
            </supplementary-material>
            <supplementary-material content-type="local-data" id="MOESM2">
              <media xlink:href="12885_2019_5820_MOESM2_ESM.jpg">
                <label>Additional file 2:</label>
                <caption>
                  <p><bold>Figure S2.</bold> Comparison of co-mutations in EGFR ex20ins (<italic>n</italic>&#x2009;=&#x2009;53),
                    ex19del (<italic>n</italic>&#x2009;=&#x2009;436), L858R (<italic>n</italic>&#x2009;=&#x2009;410),
                    T790&#x2009;M (primary and secondary mutation, <italic>n</italic>&#x2009;=&#x2009;58)
                    and other EGFR sensitive mutations (<italic>n</italic>&#x2009;=&#x2009;90).
                    Others: Other EGFR sensitive mutations, including G719X, L861Q, S768I and
                    compound mutations. (JPG 1798 kb)</p>
                </caption>
              </media>
            </supplementary-material>
          </p>
        </sec>
      </sec>
    </body>
    <back>
      <glossary>
        <title>Abbreviations</title>
        <def-list>
          <def-item>
            <term>AEs</term>
            <def>
              <p id="Par5">Adverse events</p>
            </def>
          </def-item>
          <def-item>
            <term>CT</term>
            <def>
              <p id="Par6">Computed tomography</p>
            </def>
          </def-item>
          <def-item>
            <term>EGFRex20ins</term>
            <def>
              <p id="Par7">Epidermal growth factor receptor exon 20 insertion</p>
            </def>
          </def-item>
          <def-item>
            <term>L858R</term>
            <def>
              <p id="Par8">Leu858Arg</p>
            </def>
          </def-item>
          <def-item>
            <term>MRI</term>
            <def>
              <p id="Par9">magnetic resonance imaging</p>
            </def>
          </def-item>
          <def-item>
            <term>NGS</term>
            <def>
              <p id="Par10">Next generation sequencing</p>
            </def>
          </def-item>
          <def-item>
            <term>NOS</term>
            <def>
              <p id="Par11">Non-small-cell lung cancer not otherwise specified</p>
            </def>
          </def-item>
          <def-item>
            <term>NSCLC</term>
            <def>
              <p id="Par12">Non-small-cell lung cancer</p>
            </def>
          </def-item>
          <def-item>
            <term>PD</term>
            <def>
              <p id="Par13">Progressive disease</p>
            </def>
          </def-item>
          <def-item>
            <term>PFS</term>
            <def>
              <p id="Par14">Progression-free survival</p>
            </def>
          </def-item>
          <def-item>
            <term>PR</term>
            <def>
              <p id="Par15">Partial response</p>
            </def>
          </def-item>
          <def-item>
            <term>RECIST</term>
            <def>
              <p id="Par16">Response criteria in solid tumors</p>
            </def>
          </def-item>
          <def-item>
            <term>SD</term>
            <def>
              <p id="Par17">Stable disease</p>
            </def>
          </def-item>
          <def-item>
            <term>TKIs</term>
            <def>
              <p id="Par18">Tyrosine kinase inhibitors</p>
            </def>
          </def-item>
        </def-list>
      </glossary>
      <fn-group>
        <fn>
          <p>
            <bold>Publisher&#x2019;s Note</bold>
          </p>
          <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps
            and institutional affiliations.</p>
        </fn>
        <fn>
          <p>Wenfeng Fang, Yihua Huang, Shaodong Hong, Zhonghan Zhang and Minghui Wang contributed
            equally to this work.</p>
        </fn>
      </fn-group>
      <ack>
        <title>Acknowledgements</title>
        <p>The authors would like to thank Dr. Xiaoqian Chen from OrigiMed for her excellent work in
          statistical support.</p>
      </ack>
      <notes notes-type="author-contribution">
        <title>Authors&#x2019; contributions</title>
        <p>WF, YH, SH, ZZ, MW conceived of the study; LZ and WF designed the study; YH, SH, ZZ, MW
          analyzed data; JG, WW, HG, KW collected data; WF, YH, SH, ZZ wrote the manuscript. LZ, WF
          and SH corrected and approved the final version of the manuscript. All authors read and
          approved the final manuscript.</p>
      </notes>
      <notes notes-type="funding-information">
        <title>Funding</title>
        <p>This work was financially supported by National Key R&amp;D Program of China
          (2016YFC0905500, 2016YFC0905503), Chinese National Natural Science Foundation (81772476,
          81602005, 81872499, and 81702283), Science and Technology Program of Guangdong
          (2017B020227001). All the grand supporters have no role in the design of the study and
          collection, analysis, and interpretation of data and in writing the manuscript.</p>
      </notes>
      <notes notes-type="data-availability">
        <title>Availability of data and materials</title>
        <p>The datasets used and/or analyzed during the current study are available from the
          corresponding author on reasonable request.</p>
      </notes>
      <notes>
        <title>Ethics approval and consent to participate</title>
        <p id="Par43">The study was approved by the Institutional Review Board of SYSUCC and written
          informed consent was obtained for each patient prior to sample collection. Patients were
          informed that the resected specimens were stored by the hospital and potentially used for
          scientific research, and that their privacy would be maintained. Written consents were
          obtained from parents if patients were under 16&#x2009;years old.</p>
      </notes>
      <notes>
        <title>Consent for publication</title>
        <p id="Par44">Not applicable.</p>
      </notes>
      <notes notes-type="COI-statement">
        <title>Competing interests</title>
        <p id="Par45">The authors declare that they have no competing interests.</p>
      </notes>
      <ref-list id="Bib1">
        <title>References</title>
        <ref id="CR1">
          <label>1.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Kris</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Kwiatkowski</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Iafrate</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Wistuba</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Varella-Garcia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>PF</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Using multiplexed assays of oncogenic drivers in lung cancers to select
              targeted drugs</article-title>
            <source>Jama-J Am Med Assoc</source>
            <year>2014</year>
            <volume>311</volume>
            <issue>19</issue>
            <fpage>1998</fpage>
            <lpage>2006</lpage>
            <pub-id pub-id-type="doi">10.1001/jama.2014.3741</pub-id>
          </element-citation>
        </ref>
        <ref id="CR2">
          <label>2.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Shi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>K</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Molecular epidemiology of EGFR mutations in Asian patients with advanced
              non-small-cell lung cancer of adenocarcinoma histology - mainland China subset
              analysis of the PIONEER study</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>11</issue>
            <fpage>e0143515</fpage>
            <pub-id pub-id-type="doi">10.1371/journal.pone.0143515</pub-id>
            <pub-id pub-id-type="pmid">26599344</pub-id>
          </element-citation>
        </ref>
        <ref id="CR3">
          <label>3.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Travis</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>WHO classification of the pathology and genetics of tumors of the lung</article-title>
            <source>J Thorac Oncol</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>S68</fpage>
          </element-citation>
        </ref>
        <ref id="CR4">
          <label>4.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Tsao</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>XM</given-names>
              </name>
              <name>
                <surname>Sabloff</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shigematsu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Gazdar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wistuba</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathologic characteristics of the EGFR gene mutation in non-small
              cell lung cancer</article-title>
            <source>J Thorac Oncol</source>
            <year>2006</year>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>231</fpage>
            <lpage>239</lpage>
            <pub-id pub-id-type="doi">10.1016/S1556-0864(15)31573-2</pub-id>
            <pub-id pub-id-type="pmid">17409862</pub-id>
          </element-citation>
        </ref>
        <ref id="CR5">
          <label>5.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>SI</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Somatic mutations in epidermal growth factor receptor signaling pathway
              genes in non-small cell lung cancers</article-title>
            <source>J Thorac Oncol</source>
            <year>2010</year>
            <volume>5</volume>
            <issue>11</issue>
            <fpage>1734</fpage>
            <lpage>1740</lpage>
            <pub-id pub-id-type="doi">10.1097/JTO.0b013e3181f0beca</pub-id>
            <pub-id pub-id-type="pmid">20881644</pub-id>
          </element-citation>
        </ref>
        <ref id="CR6">
          <label>6.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Tokumo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toyooka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kiura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shigematsu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tomii</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aoe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ichimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsukuda</surname>
                <given-names>K</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>The relationship between epidermal growth factor receptor mutations and
              clinicopathologic features in non-small cell lung cancers</article-title>
            <source>Clin Cancer Res</source>
            <year>2005</year>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>1167</fpage>
            <lpage>1173</lpage>
            <pub-id pub-id-type="pmid">15709185</pub-id>
          </element-citation>
        </ref>
        <ref id="CR7">
          <label>7.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Rosell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Queralt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Porta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cardenal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Camps</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Majem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopez-Vivanco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Isla</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Provencio</surname>
                <given-names>M</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Screening for epidermal growth factor receptor mutations in lung cancer</article-title>
            <source>New Engl J Med</source>
            <year>2009</year>
            <volume>361</volume>
            <issue>10</issue>
            <fpage>958</fpage>
            <lpage>967</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa0904554</pub-id>
            <pub-id pub-id-type="pmid">19692684</pub-id>
          </element-citation>
        </ref>
        <ref id="CR8">
          <label>8.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Shi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Thongprasert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Khoa</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Heeroma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Itoh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cornelio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>A prospective, molecular epidemiology study of EGFR mutations in Asian
              patients with advanced non-small-cell lung cancer of adenocarcinoma histology
              (PIONEER)</article-title>
            <source>J Thorac Oncol</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>154</fpage>
            <lpage>162</lpage>
            <pub-id pub-id-type="doi">10.1097/JTO.0000000000000033</pub-id>
            <pub-id pub-id-type="pmid">24419411</pub-id>
          </element-citation>
        </ref>
        <ref id="CR9">
          <label>9.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Mok</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Thongprasert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Saijo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sunpaweravong</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Margono</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ichinose</surname>
                <given-names>Y</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</article-title>
            <source>New Engl J Med</source>
            <year>2009</year>
            <volume>361</volume>
            <issue>10</issue>
            <fpage>947</fpage>
            <lpage>957</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa0810699</pub-id>
            <pub-id pub-id-type="pmid">19692680</pub-id>
          </element-citation>
        </ref>
        <ref id="CR10">
          <label>10.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Rosell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carcereny</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gervais</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vergnenegre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Massuti</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Felip</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Palmero</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garcia-Gomez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pallares</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>JM</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Erlotinib versus standard chemotherapy as first-line treatment for
              European patients with advanced EGFR mutation-positive non-small-cell lung cancer
              (EURTAC): a multicentre, open-label, randomised phase 3 trial</article-title>
            <source>Lancet Oncol</source>
            <year>2012</year>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>239</fpage>
            <lpage>246</lpage>
            <pub-id pub-id-type="doi">10.1016/S1470-2045(11)70393-X</pub-id>
            <pub-id pub-id-type="pmid">22285168</pub-id>
          </element-citation>
        </ref>
        <ref id="CR11">
          <label>11.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Sequist</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>O'Byrne</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hirsh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mok</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Geater</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Orlov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>M</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Phase III study of afatinib or cisplatin plus pemetrexed in patients with
              metastatic lung adenocarcinoma with EGFR mutations</article-title>
            <source>J Clin Oncol</source>
            <year>2013</year>
            <volume>31</volume>
            <issue>27</issue>
            <fpage>3327</fpage>
            <lpage>3334</lpage>
            <pub-id pub-id-type="doi">10.1200/JCO.2012.44.2806</pub-id>
            <pub-id pub-id-type="pmid">23816960</pub-id>
          </element-citation>
        </ref>
        <ref id="CR12">
          <label>12.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Soria</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ohe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Vansteenkiste</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reungwetwattana</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chewaskulyong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Dechaphunkul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Imamura</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nogami</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kurata</surname>
                <given-names>T</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Osimertinib in untreated EGFR-mutated advanced non-small-cell lung Cancer</article-title>
            <source>New Engl J Med</source>
            <year>2018</year>
            <volume>378</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <lpage>125</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa1713137</pub-id>
            <pub-id pub-id-type="pmid">29151359</pub-id>
          </element-citation>
        </ref>
        <ref id="CR13">
          <label>13.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small
              cell lung cancer (NSCLC) harboring uncommon EGFR mutations: a real-world study in
              China</article-title>
            <source>Lung Cancer</source>
            <year>2016</year>
            <volume>96</volume>
            <fpage>87</fpage>
            <lpage>92</lpage>
            <pub-id pub-id-type="doi">10.1016/j.lungcan.2016.01.018</pub-id>
            <pub-id pub-id-type="pmid">27133756</pub-id>
          </element-citation>
        </ref>
        <ref id="CR14">
          <label>14.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Klughammer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brugger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cappuzzo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ciuleanu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mok</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Delmar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Klingelschmitt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>AY</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Examining treatment outcomes with Erlotinib in patients with advanced
              non-small cell lung cancer whose Tumors Harbor uncommon EGFR mutations</article-title>
            <source>J Thorac Oncol</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>545</fpage>
            <lpage>555</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jtho.2015.12.107</pub-id>
            <pub-id pub-id-type="pmid">26773740</pub-id>
          </element-citation>
        </ref>
        <ref id="CR15">
          <label>15.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yasuda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yun</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Sng</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Lucena-Araujo</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yeo</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Huberman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Nakayama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ishioka</surname>
                <given-names>K</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Structural, biochemical, and clinical characterization of epidermal
              growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer</article-title>
            <source>Sci Transl Med</source>
            <year>2013</year>
            <volume>5</volume>
            <issue>216</issue>
            <fpage>216ra177</fpage>
            <pub-id pub-id-type="doi">10.1126/scitranslmed.3007205</pub-id>
            <pub-id pub-id-type="pmid">24353160</pub-id>
          </element-citation>
        </ref>
        <ref id="CR16">
          <label>16.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Arcila</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Nafa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chaft</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Rekhtman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reva</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Zakowski</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Kris</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ladanyi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence,
              molecular heterogeneity, and Clinicopathologic characteristics</article-title>
            <source>Mol Cancer Ther</source>
            <year>2013</year>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>220</fpage>
            <lpage>229</lpage>
            <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0620</pub-id>
            <pub-id pub-id-type="pmid">23371856</pub-id>
          </element-citation>
        </ref>
        <ref id="CR17">
          <label>17.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Riess</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Gandara</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Frampton</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Madison</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peled</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bufill</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ignatius Ou</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>McPherson</surname>
                <given-names>J</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Diverse EGFR exon 20 insertions and co-occurring molecular alterations
              identified by comprehensive genomic profiling of non-small cell lung Cancer</article-title>
            <source>J Thorac Oncol</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>1560</fpage>
            <lpage>1568</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jtho.2018.06.019</pub-id>
            <pub-id pub-id-type="pmid">29981927</pub-id>
          </element-citation>
        </ref>
        <ref id="CR18">
          <label>18.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Oxnard</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Nishino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dahlberg</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Lindeman</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Butaney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jackman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Janne</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Natural history and molecular characteristics of lung cancers harboring
              EGFR exon 20 insertions</article-title>
            <source>J Thorac Oncol</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <lpage>184</lpage>
            <pub-id pub-id-type="doi">10.1097/JTO.0b013e3182779d18</pub-id>
            <pub-id pub-id-type="pmid">23328547</pub-id>
          </element-citation>
        </ref>
        <ref id="CR19">
          <label>19.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Naidoo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sima</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Busby</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nafa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ladanyi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riely</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Kris</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Arcila</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Epidermal growth factor receptor exon 20 insertions in advanced lung
              adenocarcinomas: clinical outcomes and response to erlotinib</article-title>
            <source>Cancer</source>
            <year>2015</year>
            <volume>121</volume>
            <issue>18</issue>
            <fpage>3212</fpage>
            <lpage>3220</lpage>
            <pub-id pub-id-type="doi">10.1002/cncr.29493</pub-id>
            <pub-id pub-id-type="pmid">26096453</pub-id>
          </element-citation>
        </ref>
        <ref id="CR20">
          <label>20.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ning</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wery</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>QX</given-names>
              </name>
            </person-group>
            <article-title>NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of
              kinase domain responds poorly to known EGFR inhibitors</article-title>
            <source>Int J Cancer</source>
            <year>2016</year>
            <volume>139</volume>
            <issue>1</issue>
            <fpage>171</fpage>
            <lpage>176</lpage>
            <pub-id pub-id-type="doi">10.1002/ijc.30047</pub-id>
            <pub-id pub-id-type="pmid">26891175</pub-id>
          </element-citation>
        </ref>
        <ref id="CR21">
          <label>21.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yasuda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>EGFR exon 20 insertion mutations in non-small-cell lung cancer:
              preclinical data and clinical implications</article-title>
            <source>Lancet Oncol</source>
            <year>2012</year>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>e23</fpage>
            <lpage>e31</lpage>
            <pub-id pub-id-type="doi">10.1016/S1470-2045(11)70129-2</pub-id>
            <pub-id pub-id-type="pmid">21764376</pub-id>
          </element-citation>
        </ref>
        <ref id="CR22">
          <label>22.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sequist</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Geater</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Mok</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Clinical activity of afatinib in patients with advanced non-small-cell
              lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of
              LUX-lung 2, LUX-lung 3, and LUX-lung 6</article-title>
            <source>Lancet Oncol</source>
            <year>2015</year>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>830</fpage>
            <lpage>838</lpage>
            <pub-id pub-id-type="doi">10.1016/S1470-2045(15)00026-1</pub-id>
            <pub-id pub-id-type="pmid">26051236</pub-id>
          </element-citation>
        </ref>
        <ref id="CR23">
          <label>23.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Keam</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Heo</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Rare and complex mutations of epidermal growth factor receptor, and
              efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer</article-title>
            <source>Int J Clin Oncol</source>
            <year>2014</year>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>594</fpage>
            <lpage>600</lpage>
            <pub-id pub-id-type="doi">10.1007/s10147-013-0602-1</pub-id>
            <pub-id pub-id-type="pmid">23912954</pub-id>
          </element-citation>
        </ref>
        <ref id="CR24">
          <label>24.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Robichaux</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Elamin</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Poteete</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Estrada-Bernal</surname>
                <given-names>A</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective
              kinase inhibitor in non-small cell lung cancer</article-title>
            <source>Nat Med</source>
            <year>2018</year>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>638</fpage>
            <lpage>646</lpage>
            <pub-id pub-id-type="doi">10.1038/s41591-018-0007-9</pub-id>
            <pub-id pub-id-type="pmid">29686424</pub-id>
          </element-citation>
        </ref>
        <ref id="CR25">
          <label>25.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>van Veggel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>de Langen</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Hashemi</surname>
                <given-names>SMS</given-names>
              </name>
              <name>
                <surname>Monkhorst</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Heideman</surname>
                <given-names>DAM</given-names>
              </name>
              <name>
                <surname>Thunnissen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Smit</surname>
                <given-names>EF</given-names>
              </name>
            </person-group>
            <article-title>Afatinib and Cetuximab in four patients with EGFR exon 20
              insertion-positive advanced NSCLC</article-title>
            <source>J Thorac Oncol</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>1222</fpage>
            <lpage>1226</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jtho.2018.04.012</pub-id>
            <pub-id pub-id-type="pmid">29702285</pub-id>
          </element-citation>
        </ref>
        <ref id="CR26">
          <label>26.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Masuzawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hamamoto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nukaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Naoki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Soejima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Betsuyaku</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Characterization of the efficacies of osimertinib and nazartinib against
              cells expressing clinically relevant epidermal growth factor receptor mutations</article-title>
            <source>Oncotarget</source>
            <year>2017</year>
            <volume>8</volume>
            <issue>62</issue>
            <fpage>105479</fpage>
            <lpage>105491</lpage>
            <pub-id pub-id-type="doi">10.18632/oncotarget.22297</pub-id>
            <pub-id pub-id-type="pmid">29285266</pub-id>
          </element-citation>
        </ref>
        <ref id="CR27">
          <label>27.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Hirano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hamamoto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oashi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ishioka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Arai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nukaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miyawaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawada</surname>
                <given-names>I</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>In vitro modeling to determine mutation specificity of EGFR tyrosine
              kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung
              cancer</article-title>
            <source>Oncotarget</source>
            <year>2015</year>
            <volume>6</volume>
            <issue>36</issue>
            <fpage>38789</fpage>
            <lpage>38803</lpage>
            <pub-id pub-id-type="doi">10.18632/oncotarget.5887</pub-id>
            <pub-id pub-id-type="pmid">26515464</pub-id>
          </element-citation>
        </ref>
        <ref id="CR28">
          <label>28.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Floc'h</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Riess</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Orme</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Staniszewska</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Menard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cuomo</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Finlay</surname>
                <given-names>MRV</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>Antitumor activity of Osimertinib, an irreversible mutant-selective EGFR
              tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertions</article-title>
            <source>Mol Cancer Ther</source>
            <year>2018</year>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>885</fpage>
            <lpage>896</lpage>
            <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0758</pub-id>
            <pub-id pub-id-type="pmid">29483211</pub-id>
          </element-citation>
        </ref>
        <ref id="CR29">
          <label>29.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ruan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kannan</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Altered conformational landscape and dimerization dependency underpins
              the activation of EGFR by alphaC-beta4 loop insertion mutations</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2018</year>
            <volume>115</volume>
            <issue>35</issue>
            <fpage>E8162</fpage>
            <lpage>E8171</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.1803152115</pub-id>
            <pub-id pub-id-type="pmid">30104348</pub-id>
          </element-citation>
        </ref>
        <ref id="CR30">
          <label>30.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Eisenhauer</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Therasse</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bogaerts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Sargent</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dancey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arbuck</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gwyther</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mooney</surname>
                <given-names>M</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>New response evaluation criteria in solid tumours: revised RECIST
              guideline (version 1.1)</article-title>
            <source>Eur J Cancer</source>
            <year>2009</year>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>228</fpage>
            <lpage>247</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id>
            <pub-id pub-id-type="pmid">19097774</pub-id>
          </element-citation>
        </ref>
        <ref id="CR31">
          <label>31.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Tu</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>ZH</given-names>
              </name>
              <etal />
            </person-group>
            <article-title>A comprehensive review of uncommon EGFR mutations in patients with
              non-small cell lung cancer</article-title>
            <source>Lung Cancer</source>
            <year>2017</year>
            <volume>114</volume>
            <fpage>96</fpage>
            <lpage>102</lpage>
            <pub-id pub-id-type="doi">10.1016/j.lungcan.2017.11.005</pub-id>
            <pub-id pub-id-type="pmid">29173773</pub-id>
          </element-citation>
        </ref>
        <ref id="CR32">
          <label>32.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Shen</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Hsia</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Comparing the effects of afatinib with gefitinib or Erlotinib in patients
              with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth
              factor receptor mutations</article-title>
            <source>Lung Cancer</source>
            <year>2017</year>
            <volume>110</volume>
            <fpage>56</fpage>
            <lpage>62</lpage>
            <pub-id pub-id-type="doi">10.1016/j.lungcan.2017.06.007</pub-id>
            <pub-id pub-id-type="pmid">28676220</pub-id>
          </element-citation>
        </ref>
        <ref id="CR33">
          <label>33.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Piotrowska</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Fintelmann</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Sequist</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Jahagirdar</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Response to Osimertinib in an EGFR exon 20 insertion-positive lung
              adenocarcinoma</article-title>
            <source>J Thorac Oncol</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>e204</fpage>
            <lpage>e206</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jtho.2018.05.017</pub-id>
            <pub-id pub-id-type="pmid">30244855</pub-id>
          </element-citation>
        </ref>
        <ref id="CR34">
          <label>34.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Case report: Osimertinib achieved remarkable and sustained disease
              control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation
              complex</article-title>
            <source>Lung Cancer</source>
            <year>2018</year>
            <volume>121</volume>
            <fpage>1</fpage>
            <lpage>4</lpage>
            <pub-id pub-id-type="doi">10.1016/j.lungcan.2018.04.006</pub-id>
            <pub-id pub-id-type="pmid">29858019</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </article>
</pmc-articleset>
